Bruker Corporation · NASDAQ:BRKR
Bruker — 38th Annual JP Morgan Healthcare Conference 2020
28 slides from Bruker's conference presentation, Jan 13, 2020
Slide 1: JP Morgan 2020 Healthcare Conference
Bruker Corporation Bruker Corporation JP Morgan JP Morgan 2020 2020 Healthcare Healthcare Conference Conference January 13, January 13, 2020 2020 ©©Bruker BrukerCorporation Corporation Innovation with Integrity Innovation with Integrity
Slide 2: Safe Harbor Statement
Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
Slide 3: Bruker History & Recent New Platform Introductions
Bruker History & Recent New Platform Introductions 60 Years of Innovation 2013-today Multiphoton, super- 2008 resolution and light- Bruker Corp. sheet microscopy; 1960 2000 merges with semi X-Ray metrology Bruker co-founded Biospin and photo mask repair by Prof. G. Laukien Bruker 1980s-today Daltoni
Slide 4: Bruker Overview: Revenue Mix
Bruker Overview Our Revenue mix as % of LTM revenue Business Group Mix Geographic Mix Bruker Scientific Instruments Segment Market Mix Academic & Govt 45% Research BIOSPIN Industrial Research 22% Group 29.7% NANO & Other Industrial 31.0% Group 29% 36% 30% Pharma & 15% Biopharma 9.6% 29.7% Clinical M
Slide 5: Bruker Overview: People, Innovation and Global Operations
Bruker Overview Our people, innovation engine and global operations 6,900 14 1,200 4,000 + Employees Major manufacturing Employees dedicated Patents pending or sites in N. America, to R&D granted Europe and Asia 5
Slide 6: Bruker Overview: Market-Leading Positions
Bruker Overview We have achieved market-leading positions(1) NMR and EPR Preclinical Imaging: MRI, Mass Spec Imaging, Atomic Force Spectroscopy MPI, PET/MR, microCT MALDI-TOF and MRMS Microscopy (AFM) FT-IR/NIR Spectroscopy X-Ray Diffraction (XRD) Next-Gen AAFM and X-ray BEST Superconductors and and
Slide 7: Bruker's Dual Strategy
Bruker’s Dual Strategy Project Accelerate & Operational Excellence drive customer success and profitable growth • Transforming our portfolio for attractive secular growth trends • Driving key product innovation cycles Profitable • Advancing six high-growth, high- Growth margin Project Accelerate ini
Slide 8: Portfolio Transformation for Key Secular Growth Trends
Portfolio Transformation for Key Secular Growth Trends Growth drivers target well-funded areas Next-generation proteomics Beyond ss-RNA-Seq: Human Brain Project drives Precision Medicine drives In vivo life-cell microscopy, and phenomics; emergence Human Cell Atlas & neuroscience and cell clinical p
Slide 9: Project Accelerate
Project Accelerate Seeking faster revenue growth from six targeted high-growth, Proteomics & high-margin initiatives Phenomics Aftermarket Proteomics & Phenomics Aftermarket Biopharma & Services, consumables for Bruker LST & Applied High-performance NMR and MS DX solutions; emerging scientific solut
Slide 10: Project Accelerate Portfolio Roadmap – 2020 Update
Project Accelerate Portfolio Roadmap – 2020 Update Reshaping our portfolio for faster growth and higher margins* 2018 2019 2020E 2021E 2022E 2023E timsTOF Pro 4D Proteomics, 4D Lipidomics; 1.0 GHz NMR Proteomics & Phenomics 1.1-1.2 GHz NMR, SpatialOMxTM Mass spec phenomics, single cell proteomics ‘M
Slide 11: Business Updates
Business Updates © Bruker Corporation Innovation with Integrity
Slide 12: First 1.1 GHz NMR at St. Jude's Children Research Hospital
Proteomics & Phenomics First 1.1 GHz NMR At St. Jude’s Children Research Hospital • Installation of world’s first 1.1 GHz NMR completed • A major technical milestone after almost a decade of R&D • Similar hybrid LTS/HTS technology used in 1.2 GHz NMR “We are thrilled to have received the first 1.1 G
Slide 13: First 1.2 GHz NMR Spectrometer Shipped
Proteomics & Phenomics First 1.2 GHz NMR Spectrometer Shipped Q4 2019 Developments: • First 1.2 GHz NMR order received in the US • First 1.2 GHz NMR order received in APAC (Korea) • First 1.2 GHz NMR shipped; installation planned in H1 2020 • Peer-reviewed scientific publications highlight unique va
Slide 14: timsTOF Pro: Unlocking the Transformative Power of Proteomics
Proteomics & Phenomics TimsTOF ProTM: Unlocking the Transformative Power of Proteomics Plasma Proteomics Body (Bench-to-Bed Side) Pioneering 4D proteomics for large cohort Fluids studies Pharmaco-Proteomics • Superior robustness (Therapy response/Patient stratification) • ‘CCS-aware’ algorithms high
Slide 15: Expanding Our TAM Through Product Innovation and Select Acquisitions
Microbiology & Diagnostics Expanding Our TAM Through Product Innovation and Select Acquisitions Existing Products New Products • MALDI Biotyper installed base approximately 3,800 systems Fast ID Market Product • >160 million pathogen IDs per year on MALDI Biotyper systems Penetration Development • M
Slide 16: Sepsityper: Fast Identification From Positive Blood Cultures
Microbiology & Diagnostics Sepsityper®: Fast Identification From Positive Blood Cultures Sepsis • When every hour counts Direct ID from positive blood culture (PBC) • ID possible in 15-20 minutes after PBC alert • Efficient and faster results to treating physicians • Enabling change of therapy with
Slide 17: Sepsityper: Fast ID From Positive Blood Cultures (PBCs)
Microbiology & Diagnostics Sepsityper®: Fast ID From Positive Blood Cultures (PBCs) Sepsis • When every hour counts Blood Collection Blood Culture BC Sample Preparation Organism Identification (BC) System MBT Sepsityper® US IVD Kit MALDI Biotyper® CA System with FDA Review Pending methods for PBC sa
Slide 18: NMR FoodScreener for Product Authenticity Testing
Applied Markets NMR FoodScreener™ for Product Authenticity Testing FoodScreenerTM Example • Detect Honey Adulteration 18
Slide 19: Financial Performance
Financial Performance © Bruker Corporation Innovation with Integrity
Slide 20: Revenue Growth & Distribution
Revenue Growth & Distribution Solid Revenue Growth Driven Organically and by Acquisitions Revenue Growth By Geography By Business Group $2.03B BIOSPIN Group $1.9B APAC 30% 29.7% 31% NANO Group $1.8B Europe 36% $1.6B 5% 9.6% 29% Rest of World 29.7% BEST Group Americas CALID Group 2016A 2017A 2018A LT
Slide 21: Margin Expansion & Profitability
Margin Expansion & Profitability Non-GAAP Operating Profit Margin Non-GAAP EPS (OPM) $1.58 17.5% 16.8% 15.9% $1.40 15.0% $1.19 $1.21 2016A 2017A 2018A LTM 9/30/19 2016A 2017A 2018A LTM 9/30/19 Drivers Volume and Product Mix Operational Excellence Operational Scalability & Portfolio • MALDI Biotyper
Slide 22: Debt Financing
Debt Financing Supports Corporate Strategic Objectives, Accretive to EPS in 2020 and Beyond • Capitalized on low interest rate environment in US Bruker Long-Term Debt(1)(2) and European financial markets $ in millions $300 $300 • Enhanced financial flexibility to fund corporate strategic objectives
Slide 23: Capital Deployment Strategy
Capital Deployment Strategy Invest Maintain Return in Growing the Business Financial Flexibility Capital to Shareholders • R&D investments • Strong, flexible balance sheet • Current targeted annual • Market Development • Conservative debt levels dividend of $0.16 per share • CapEx investments • Peri
Slide 24: Questions and Answers
Questions and Answers © Bruker Corporation Innovation with Integrity
Slide 25: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, 2016 (1) 2017 (1) 2018 2018 2019 2019 R
Slide 26: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, 2016 (1) 2017 (1) 2018 2018 2019 2019 R
Slide 27: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, 2016 (1) 2017 (1) 2018 2018 2019 2019 R
Slide 28: Reconciliation of GAAP to Non-GAAP Financial Measures
Bruker Corporation Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Nine Months Last Twelve Ended Ended Months Ended (in millions, except per share amounts) Twelve Months Ended December 31, December 31, September 30, September 30, 2016 (1) 2017 (1) 2018 2018 2019 2019 R
Bruker — 38th Annual JP Morgan Healthcare Conference 2020 on 6ix